Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Broad immune response may be needed to destroy latent HIV

By R&D Editors | January 8, 2015

A major barrier to finding a cure for HIV/AIDS is the presence of latent HIV in the cells of chronically infected individuals. But a team of Yale and Johns Hopkins researchers may have pinpointed a strategy for eliminating the residual virus.

The study is published online by Nature.

Despite treatment with antiretroviral therapy, HIV persists in patients in a latent reservoir. Yale researchers and their co-authors at Johns Hopkins University, the Univ. of California-San Francisco, and Regeneron Pharmaceuticals explored the question of whether specific immune cells known as killer T cells, or CTLs, could be stimulated to effectively target and destroy infected cells that harbor dormant viruses. The results of this study have major implications for the design and development of a therapeutic vaccine to cure HIV patients, said the researchers.  

In their investigation, the researchers first studied the viral DNA of two groups of 25 HIV patients, including 10 who had started antiviral therapy within first three months of infection and 15 who had already been chronically infected before receiving therapy. They found that the viral reservoirs of chronically infected individuals were dominated by “escape mutations,” or variants that allow HIV to evade detection by CTLs.

“These results help explain why none of the current vaccines can clear HIV from the body,” said Liang Shan, a postdoctoral fellow at Yale School of Medicine and co-senior author of the paper. “The next question was how, given a boost, CTLs could recognize and kill infected cells despite the escape mutations.”

Led by Dr. Robert Siliciano, co-senior author and professor of medicine at Johns Hopkins University, the researchers addressed this question by exposing CTLs isolated from patients to mixed pieces of HIV proteins and then observing their function in vitro. They found that with this stimulation, the CTLs could provide a more broad and effective immune response that targeted unmutated portions of HIV proteins. Residual HIV from both groups of patients could be targeted by the newly stimulated CTLs.  

“The next big thing was to test this strategy outside the petri dishes,” said co-senior author Richard Flavell, chair and Sterling Professor of Immunobiology at Yale School of Medicine. To that end, the researchers also conducted a small-scale preclinical trial using “humanized” mice carrying HIV-patient immune system. In the vaccine group, the stimulated CTLS that targeted unmutated HIV epitopes were able to control the infection, and in some mice, they cleared the circulating virus. In the placebo group, HIV infection rapidly progressed in the mice.  

“Our study suggests that directing CTL responses to unaltered pieces of virus may be the future direction for the development of therapeutic vaccine to clear HIV,” said Shan.

Flavell added, “Another important implication coming from this study is that it shows the great value of reconstructing a patient immune system in mice in the studies of a disease, such as infection or cancer, and suggests how this can be of value in the development of medicines.”

Source: Yale Univ.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE